Logo

Fluidic Analytics: Joe Keegan

Sep 23, 2019

Fluidic Analytics has appointed Joe Keegan as the firm's chairman. Keegan currently serves on the boards of Bio-Techne and Interpace Diagnostics, as well as a number of early- and growth-stage companies in the life sciences tools and diagnostic industries. Prior to Fluidic Analytics, Keegan served as CEO as ForteBio until it was sold to Pall Corporation. Before ForteBio, Keegan was CEO of Molecular Devices. Keegan has also held the role of chairman of the Analytical Life Science & Diagnostics Association, non-executive chairman of Labcyte, and non-executive director of Advanced Cellular Diagnostics, ProteinSimple, and Seahorse Bioscience.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.